Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.

Publication ,  Journal Article
Dording, C; Cassiello, C; King, F; Pencina, M; Fava, M; Mischoulon, D
Published in: Int Clin Psychopharmacol
September 2013

We have recently examined the efficacy of low-dose aripiprazole augmentation for major depressive disorder (MDD), with modest nonsignificant benefit found. In a secondary investigation, we examined whether aripiprazole resulted in improvement in four subscales (depression, anxiety, somatic symptoms, and hostility) of the Kellner Symptom Questionnaire (KSQ). We reanalyzed data from the main outcome study on 221 MDD patients with inadequate response to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. Patients were randomized, using the sequential parallel comparison design, into two 30-day phases, as follows: drug/drug (aripiprazole 2 mg/day in phase 1, aripiprazole 5 mg/day in phase 2), placebo/drug (placebo in phase 1, aripiprazole 2 mg/day in phase 2), or placebo/placebo (placebo in both phases). We examined changes in the KSQ score from baseline to endpoint on the basis of the subscaled Well-being and Reversal Distressed Anxiety Subscales. The score for the KSQ depression subscale improved from baseline to the end of follow-up, with a significant advantage for aripiprazole over placebo (P=0.0327). Although improvement was also observed in the anxiety and hostility scales, neither attained a significant advantage over placebo; no significant change was observed for the somatization subscale. Aripiprazole augmentation resulted in a significant improvement compared with placebo augmentation only in the depression subscale of the KSQ; however, the low dose may not have been enough to have an impact on the anxiety and hostility scales. The good tolerability of the low dose may have resulted in the absence of worsening of somatic symptoms. Prospective studies are needed to better characterize the impact of low doses of aripiprazole augmentation on different manifestations of MDD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int Clin Psychopharmacol

DOI

EISSN

1473-5857

Publication Date

September 2013

Volume

28

Issue

5

Start / End Page

238 / 244

Location

England

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Quinolones
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Piperazines
  • Middle Aged
  • Male
  • Humans
  • Hostility
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dording, C., Cassiello, C., King, F., Pencina, M., Fava, M., & Mischoulon, D. (2013). The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol, 28(5), 238–244. https://doi.org/10.1097/YIC.0b013e32836220df
Dording, Christina, Clair Cassiello, Franklin King, Michael Pencina, Maurizio Fava, and David Mischoulon. “The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.Int Clin Psychopharmacol 28, no. 5 (September 2013): 238–44. https://doi.org/10.1097/YIC.0b013e32836220df.
Dording C, Cassiello C, King F, Pencina M, Fava M, Mischoulon D. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol. 2013 Sep;28(5):238–44.
Dording, Christina, et al. “The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.Int Clin Psychopharmacol, vol. 28, no. 5, Sept. 2013, pp. 238–44. Pubmed, doi:10.1097/YIC.0b013e32836220df.
Dording C, Cassiello C, King F, Pencina M, Fava M, Mischoulon D. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol. 2013 Sep;28(5):238–244.

Published In

Int Clin Psychopharmacol

DOI

EISSN

1473-5857

Publication Date

September 2013

Volume

28

Issue

5

Start / End Page

238 / 244

Location

England

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Quinolones
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Piperazines
  • Middle Aged
  • Male
  • Humans
  • Hostility